The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma

Opinion
Video

Hussein Tawbi, MD, PhD, explains that LAG-3 is a marker of T-cell exhaustion, and combining LAG-3 inhibitors with PD-1 inhibitors can reverse this exhaustion, enhancing T-cell effectiveness and showing therapeutic benefits in patients with metastatic melanoma.

Recent Videos
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Solly Chedid, MD, an expert on MDS
Related Content
Long-Term Success With Anti–LAG-3/Anti–PD-1 Combo in Metastatic Melanoma

Long-Term Success With Anti–LAG-3/Anti–PD-1 Combo in Metastatic Melanoma

Sabrina Serani
October 11th 2024
Article

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the treatment of metastatic melanoma.

Read More

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen

TH17 Cells May Serve as Biomarker in Metastatic Melanoma

TH17 Cells May Serve as Biomarker in Metastatic Melanoma

Morgan Bayer
September 28th 2024
Article

TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

Nichole Tucker;Richard Carvajal, MD
April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

Melanoma Treatment Gets a Boost With Fianlimab and Cemiplimab

Melanoma Treatment Gets a Boost With Fianlimab and Cemiplimab

Jax DiEugenio
September 17th 2024
Article

Fianlimab combined with cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma, regardless of LAG-3 or PD-L1 expression.

Read More

Atezolizumab After Vemurafenib and Cobimetinib Shows Trend Toward Better OS in Melanoma

Atezolizumab After Vemurafenib and Cobimetinib Shows Trend Toward Better OS in Melanoma

Megan Hollasch
September 15th 2024
Article

Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not statistically significant.

Read More